487 related articles for article (PubMed ID: 30089615)
1. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
2. CSF biomarkers and clinical progression of Parkinson disease.
Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
[TBL] [Abstract][Full Text] [Related]
3. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
Yousaf T; Pagano G; Niccolini F; Politis M
J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
[TBL] [Abstract][Full Text] [Related]
4. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
Nabizadeh F; Pirahesh K; Valizadeh P
J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
[TBL] [Abstract][Full Text] [Related]
5. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus and Parkinson disease.
Pagano G; Polychronis S; Wilson H; Giordano B; Ferrara N; Niccolini F; Politis M
Neurology; 2018 May; 90(19):e1654-e1662. PubMed ID: 29626177
[TBL] [Abstract][Full Text] [Related]
7. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD.
Arnaldi D; Morbelli S; Brugnolo A; Girtler N; Picco A; Ferrara M; Accardo J; Buschiazzo A; de Carli F; Pagani M; Nobili F
Parkinsonism Relat Disord; 2016 Aug; 29():47-53. PubMed ID: 27264343
[TBL] [Abstract][Full Text] [Related]
8. CSF β-amyloid
Kim R; Lee J; Kim HJ; Kim A; Jang M; Jeon B; Kang UJ
Neurology; 2019 Jan; 92(1):e40-e47. PubMed ID: 30504429
[TBL] [Abstract][Full Text] [Related]
9. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
10. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia.
Vendette M; Gagnon JF; Décary A; Massicotte-Marquez J; Postuma RB; Doyon J; Panisset M; Montplaisir J
Neurology; 2007 Nov; 69(19):1843-9. PubMed ID: 17984452
[TBL] [Abstract][Full Text] [Related]
11. REM sleep behavior disorder in early Parkinson's disease predicts the rapid dopaminergic denervation.
Kim YE; Kim YJ; Hwang HS; Ma HI
Parkinsonism Relat Disord; 2020 Nov; 80():120-126. PubMed ID: 32987358
[TBL] [Abstract][Full Text] [Related]
12. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
13. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
[TBL] [Abstract][Full Text] [Related]
14. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
[TBL] [Abstract][Full Text] [Related]
15. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
Stiasny-Kolster K; Doerr Y; Möller JC; Höffken H; Behr TM; Oertel WH; Mayer G
Brain; 2005 Jan; 128(Pt 1):126-37. PubMed ID: 15548552
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
[TBL] [Abstract][Full Text] [Related]
17. Speech difficulties in early de novo patients with Parkinson's disease.
Polychronis S; Niccolini F; Pagano G; Yousaf T; Politis M
Parkinsonism Relat Disord; 2019 Jul; 64():256-261. PubMed ID: 31078401
[TBL] [Abstract][Full Text] [Related]
18. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
19. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
[TBL] [Abstract][Full Text] [Related]
20. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
